Clinical trials: Drug Withdrawal
MMR on 12 Month
A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML
patients with Ph+ CML-CP who have been treated with second-generation TKIs (nilotinib, dasatinib) for at least 3 years and maintains MMR for at least 2 years, continue to be treated with halved dose for 12 months, and then stop…
- Trial name
- NCT05341050
- Testing
- TKI
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- xuna
Chronic Non-specific Low Back Pain
Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain
Analysis of the efficacy, maintenance of efficacy, long-term safety, and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in the treatment of patients with chronic…
- Trial name
- NCT04940741
- Testing
- VER-01
- Where
- Germany
- Volunteers
- 820 people
- Sponsor
- Vertanical GmbH
Withdrawal Syndrome
Protocolized Sedative Weaning VS. Usual Care in Pediatric Critically Ill, RCT
Sedative and analgesic agents are widely used in the ICU. These agents can provide hypnotic effect, pain alleviation, cooperation, and synchronizing ventilatory support.
- Trial name
- NCT03018977
- Testing
- The sedative weaning protocol group, The usual group
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Ramathibodi Hospital
Alcohol Withdrawal Syndrome(AWS)
Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam
The purpose of this study was to evaluate if the medication Gabapentin, which is not approved for the treatment of alcohol withdrawal, is effective in the treatment of alcohol withdrawal syndrome compared to treatment with…
- Trial name
- NCT00229125
- Testing
- Gabapentin, Lorazepam
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Withdrawal Syndrome
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when…
- Trial name
- NCT05438641
- Testing
- BZDP-Sparing Protocol, BZDP-Based Protocol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Juvenile Idiopathic Arthritis (JIA)
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
Biologic therapies made clinical remission an achievable goal for most juvenile idiopathic arthritis (JIA) patients. Nevertheless, antirheumatic drugs have side effects and are costly.
- Trial name
- Re-JIA (NCT06618937)
- Testing
- Treatment medication withdrawal strategy
- Where
- Italy
- Volunteers
- 166 people
- Sponsor
- Istituto Giannina Gaslini
Focal Epilepsy
Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring
ProbCluster trial aims at making the proof of concept of antiseizure efficacy of the old antigout PBN in SC, in which Panx1 involvement is relevant on SC pathophysiology and in which efficient therapies are still lacking.
- Trial name
- PROBCLUSTER (NCT07318870)
- Testing
- Probenecid
- Where
- 2 sites in France
- Volunteers
- 600 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Substance Withdrawal Syndrome
Efficacy of XYZ for Withdrawal Syndrome
This is a randomized controlled clinical trial to explore the efficacy and mechanism of Tiaozhong-Yiqi Decoction (TZYD) in treating substance withdrawal syndrome, combining network pharmacology analysis and clinical validation.
- Trial name
- TZYT-WS (NCT07543809)
- Testing
- Tiaozhong-Yiqi Decoction, routine care
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chongqing Jiangbei Hospital of Traditional Chinese Medicine
Cardiotoxicity, HER2-positive Breast Cancer
Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction
Breast cancer is the most common cancer in the United Kingdom (UK), but improvements in treatment mean 3 in 4 people survive for more than 10 years.
- Conditions
- Cardiotoxicity, HER2-positive Breast Cancer, Heart Failure, Cancer, Therapy-Related
- Trial name
- HER-SAFE (NCT05880160)
- Testing
- Phased withdrawal of heart failure medications
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- University College, London
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Neurostimulation to Improve NOWS Outcomes
The objective of this study is to determine if tAN therapy can reduce the median number of days of oral morphine administered to an infant after start of treatment.
- Trial name
- SPROUT (NCT05129020)
- Testing
- Sparrow Fledging Therapy System
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Spark Biomedical, Inc.
Alcohol Abuse, Alcoholism
Consequences of At-risk Alcohol Consumption in ICU Patients
At-risk drinking is known to cause a high incidence of alcohol withdrawal syndrome which has a high impact on morbidity and mortality.
- Trial name
- NCT03565016
- Testing
- no interventional study
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence syndrome.
- Conditions
- Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
- Trial name
- NCT04298853
- Testing
- Morphine PRN, Morphine scheduled
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indiana University
Healthy Volunteer Study
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
- Trial name
- NCT07314346
- Testing
- Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Neonatal Opioid Withdrawal Syndrome
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome
- Trial name
- NOWSHINE (NCT04104646)
- Testing
- CHF6563, Morphine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Pain, Low Back Pain
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
The primary objective of the study is to determine the analgesic efficacy and safety of ALO-02 extended-release capsules, when compared to placebo, in subjects with moderate to severe chronic low back pain.
- Conditions
- Chronic Pain, Low Back Pain, Analgesia
- Trial name
- NCT01571362
- Testing
- ALO-02
- Where
- 52 sites in United States
- Volunteers
- 410 people
- Sponsor
- Pfizer
Autoimmune Diseases
Withdraw Drug in Stable IgG4-Related Disease
Evaluation and prediction of relapse risk after glucocorticoid or immunosuppressant withdrawal in patients with stable IgG4 related disease: a prospective cohort study from china.
- Trial name
- NCT04124861
- Testing
- Drug free, IS monotherapy and GC combined with IS
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Peking Union Medical College Hospital
Cancer Related Pain
NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
This is a multi-centre, long term, double blind, clinical protocol for NanaBis™ as a monotherapy treatment in participants 18-75 years of age with cancer related pain.
- Trial name
- NCT04808531
- Testing
- NanaBis™, Oxycodone CR, Oxycodone IR
- Volunteers
- 360 people
- Sponsor
- Medlab Clinical
Alcohol Withdrawal Delirium, Alcohol Withdrawal
Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
Severe acute alcohol withdrawal syndrome is a potentially life-threatening condition characterized by agitation, confusion, abnormal heart rhythms and seizures.
- Conditions
- Alcohol Withdrawal Delirium, Alcohol Withdrawal, Alcohol Withdrawal Seizures
- Trial name
- PHENOMANAL (NCT03586089)
- Testing
- Phenobarbital Sodium
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Unity Health Toronto
Chronic Pain, Drug Dependence of Morphine Type
Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
The proposed clinical trial will address the problem of opioid withdrawal. Opioids are essential for pain-relief in the short term, but their continued use is associated with a host of adverse effects.
- Conditions
- Chronic Pain, Drug Dependence of Morphine Type, Symptom, Withdrawal
- Trial name
- NCT04939623
- Testing
- Probenecid
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Cardiovascular Disease Other, Bleeding
Transfusion of Cold-stored Platelet Concentrates
This study will investigate the effects of Leukocyte reduced cold-stored platelet transfusions used in treatment of immediate postoperative blood loss in patients undergoing thoracic surgery in combination with extracorporal…
- Conditions
- Cardiovascular Disease Other, Bleeding, Surgery
- Trial name
- 4CPLT (NCT02495506)
- Testing
- Cold stored platelets, Room temperature platelets
- Where
- Norway
- Volunteers
- 65 people
- Sponsor
- Haukeland University Hospital